Compare PYXS & PED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PYXS | PED |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.3M | 152.8M |
| IPO Year | 2021 | 2012 |
| Metric | PYXS | PED |
|---|---|---|
| Price | $3.75 | $11.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 939.3K | 23.0K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $13,858,000.00 | ★ $45,751,000.00 |
| Revenue This Year | N/A | $171.75 |
| Revenue Next Year | $7,043.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.67 |
| 52 Week Low | $0.97 | $0.43 |
| 52 Week High | $5.55 | $18.89 |
| Indicator | PYXS | PED |
|---|---|---|
| Relative Strength Index (RSI) | 72.22 | 42.22 |
| Support Level | $3.67 | $0.53 |
| Resistance Level | $4.58 | $13.92 |
| Average True Range (ATR) | 0.29 | 0.63 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 99.67 | 28.51 |
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).